Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors

Acta Biochimica Polonica

Volumn 54, Issue 1, 2007, Pages 125-133

  Jazowiecka Rakus, Joanna ^a   Jarosz, Magdalena ^a   Kozłowska, Dorota ^a   Sochanik, Aleksander ^a   Szala, Stanisław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Antiangiogenic; Anticancer; Combination therapy; CTX; Vasostatin

Indexed keywords

MURINAE; MUS;

EID: 33947610389     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2007_3278     Document Type: Article

References (38)

1. Atreya CD, Singh NK, Nakhasi HL (1995) The Rubella virus RNA binding activity of human calreticulin is localized to the N-terminal domain. J Virol 69: 3848-3851.
2. Brooks PC, Silletti S, Schalscha TL, Friedlander M, Cheresh DA (1998) Disruption of angiogenesis by PEX, a non-catalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391-400.
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
4. Burke PA, DeNardo SJ (2001) Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 39: 155-171.
5. Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139-145.
6. Chen Q-R, Kumar D, Stass SA, Mixson J (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308-3312.
7. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
8. Folkman J (2000) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
9. Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3: 643-651.
10. Gupta SK, Hassel T, Singh JP (1995) A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 92: 7799-7803.
11. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64: 1570-1574.
12. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
13. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
14. Jazowiecka-Rakus J, Jarosz M, Szala S (2006) Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumors. Acta Biochim Polon 53: 199-202.
15. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R (2000) Canstatin, a novel martix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2: 1209-1215.
16. Kerbel RS, Kamen B (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.
17. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24.
18. Loeffler M, Kruger JA, Reisfeld RA (2005) Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65: 5027-5030.
19. Meritet J-F, Maury C, Tovey MG (2001) Induction of tolerance to recombinant therapeutic protein. J Interferon Cytokine Res 21: 1031-1038.
20. Michalak M, Milner RE, Burns K, Opas M (1992) Calreticulin. Biochem J 285: 681-692.
21. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M (1999) Calreticulin: one protein, one gene, many functions. Biochem J 344: 281-292.
22. Mitrus I, Delić K, Wróbel N, Missol-Kolka E, Szala S (2006) Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice. Acta Biochim Polon 53: 357-360.
23. Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979.
24. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
25. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285: 1926-1928.
26. Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282: C947-C970.
27. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188: 2349-2356.
28. Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94: 2461-2468.
29. Ribatti D, Vacca A (2005) Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies. Curr Cancer Drug Targets 5: 573-578.
30. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20: 3906-3927.
31. Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24: 1720-1740.
32. Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 244: 129-135.
33. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-1334.
34. Wu Z, O'Reilly MS, Folkman J, Shing Y (1997) Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236: 651-654.
35. Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH (2005) Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 11: 28-35.
36. Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96: 1900-1905.
37. Yao L, Pike SE, Pittaluga S, Cherney B, Gupta G, Jaffe ES, Tosato G (2002a) Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 51: 358-366.
38. Yao L, Pike SE, Tosato G (2002b) Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 71: 47-53.